Earnings Preview: AtriCure to Report Financial Results on October 29
$AtriCure(ATRC.US)$ is scheduled to release its financial results on October 29 ET. Earnings PreviewAnalysts estimate $AtriCure(ATRC.US)$ to post revenue of USD112.25M for 2024Q3, up 14.21% YOY; EPS
AtriCure Announces Launch of CryoSPHERE MAX Probe for Post-Operative Pain Management
Shareholders in AtriCure (NASDAQ:ATRC) Are in the Red If They Invested Three Years Ago
AtriCure to Announce Third Quarter 2024 Financial Results
AtriCure Receives CE-Mark for the EnCompass Clamp
Here's Why TimesSquare Capital U.S. Small Cap Growth Strategy Decided to Sell AtriCure (ATRC)
Is It Time To Consider Buying AtriCure, Inc. (NASDAQ:ATRC)?
Radiofrequency Ablation Device Market Global Forecast Report and Company Analysis 2024-2032 Featuring Boston Scientific, Abbott, AtriCure, Medtronic, Stryker, Smith & Nephew, Conmed and Hologic - ResearchAndMarkets.com
AtriCure, Inc. (NASDAQ:ATRC) Soars 29% But It's A Story Of Risk Vs Reward
AtriCure Touts First Case With New FDA-cleared AtriClip Flex-Mini
AtriCure Reports First Patient Has Been Treated With The Revolutionary AtriClip FLEX-Mini Device
Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?
AtriCure Receives Expanded Indication For AtriClip In Europe For High-Risk Thromboembolism Patients, Validating Its Effectiveness In Reducing Stroke Events During Cardiac Surgery
AtriCure Receives Expanded CE-Mark Indication for AtriClip Devices for the Reduction of Stroke in Patients With Atrial Fibrillation
CCORF Maintains AtriCure(ATRC.US) With Buy Rating, Maintains Target Price $49
CCORF analyst William Plovanic maintains $AtriCure(ATRC.US)$ with a buy rating, and maintains the target price at $49.According to TipRanks data, the analyst has a success rate of 40.8% and a total
Atricure's Market Strength and Innovation Justify Buy Rating
US$39.89: That's What Analysts Think AtriCure, Inc. (NASDAQ:ATRC) Is Worth After Its Latest Results
US$40.89: That's What Analysts Think AtriCure, Inc. (NASDAQ:ATRC) Is Worth After Its Latest Results
AtriCure Second Quarter 2024 Earnings: EPS Misses Expectations
Oppenheimer Maintains AtriCure(ATRC.US) With Buy Rating, Maintains Target Price $32
Oppenheimer analyst Suraj Kalia maintains $AtriCure(ATRC.US)$ with a buy rating, and maintains the target price at $32.According to TipRanks data, the analyst has a success rate of 52.1% and a total